Reading HSDT? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track HSDT free→Reading HSDT? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track HSDT free→QuarterlyIQ Insights · HSDT
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Entry into a Material Definitive Agreement. On May 29, 2026, Solana Company (the “Company”) entered into an Amended and Restated Sales Agreement (the “Sales Agreement”) with Clear Street LLC (“Clear Street”) and Maxim Group LLC (“Maxim”) (each, an “Agent,” and, together, the “Agents”), as co-sales agents, pursuant to which the Company may offer and sell shares of the Company’s Class A common stock, par value $0.001 per share (the “Shares”) from time to time in connection with its existing “at…
of this Current Report on Form 8-K (including the accompanying Exhibit 99.1 hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filings, except as expressly incorporated…
by reference. The Put Options (as defined below) have not been registered under the Securities Act of 1933, as amended (the “Securities Act”) or the securities laws of any state, and are being offered and sold in reliance on the exemption from registration under the Securities Act, afforded by Section 4(a)(2) and/or Rule 506 promulgated thereunder.
Other Events. Registered Direct Offering On April 27, 2026, Solana Company (the “Company”) entered into securities purchase agreements (collectively, the “RDO Purchase Agreements”) with the purchasers named therein (the “Purchasers”), pursuant to which (i) the Company issued and sold to the Purchasers, in a registered direct offering (the “Registered Direct Offering”), 3,076,922 shares (the “Shares”) of the Company’s Class A common stock, $0.001 par value per share (the “Common Stock”). The o…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (b) On April 22, 2026 and April 23, 2026, Sherrie Perkins and Paul Buckman, respectively, notified Solana Company (the “Company”) of their decision to not stand for re-election as a director when their current terms expire at the Company’s 2026 Annual Meeting of Stockholders, scheduled to be held on May 21, 2026 (the “Annual Meeting”). Each of…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On April 8, 2026, Solana Company (the “Company”) and Antonella Favit-Van Pelt, MD, PhD, mutually agreed that Dr. Favit-Van Pelt would separate from the Company and resign as the Company’s Chief Medical Officer, effective as of April 8, 2026 (the “Effective Date”). In connection with her separation from the Company, the Company and Dr. Favit-Van P…
Results of Operations and Financial Condition. Appointment of Chief Operating Officer and Deputy Chief Financial Officer On March 16, 2026, Solana Company (the “Company”) appointed Agustina “Madelene” Gani Tjandrasuwita to serve as the Company’s Chief Operating Officer and Deputy Chief Financial Officer, effective April 6, 2026 (the “Effective Date”). Ms. Tjandrasuwita, age 50, was most recently the Chief Financial Officer at Hedera Hashgraph, Inc., a decentralized blockchain company, fro…
of this Current Report on Form 8-K (including the accompanying Exhibit 99.1 hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filings, except as expressly incorporated…
Results of Operations and Financial Condition. On November 18, 2025, Solana Company (formerly known as Helius Medical Technologies, Inc.) (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2025, a business update, and information regarding a conference call to discuss these financial results and recent corporate highlights. A copy of this press release is furnished herewith as Exhibit 99.1 to this Current Report and is incorporated he…
Regulation FD Disclosure. On November 5, 2025, Solana Company (formerly known as Helius Medical Technologies, Inc.) (the “Company”) issued a press release announcing that its board of directors approved a stock repurchase plan to acquire up to $100 million of the Company’s outstanding Class A common stock, $0.001 par value per share. A copy of the press release is attached hereto as Exhibit 99.2 and incorporated herein by reference. Information contained on or accessible through any websi…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Board Changes As previously disclosed, on October 30, 2025 at the special meeting of stockholders (the “Special Meeting”) of Solana Company (formerly known as Helius Medical Technologies, Inc.) (the “Company”), shareholders of the Company approved the election of Cosmo Jiang to the Company’s Board of Directors (the “Board”). Immediately followi…
Other Events. On November 3, 2025, the Company’s Board authorized a stock repurchase program for the purchase of up to $100 million of the Company’s outstanding Common Stock. Repurchases of Common Stock may be made in the open market (including through Rule 10b-18 compliant transactions), in privately negotiated transactions, in block trades, through one or more accelerated share repurchase transactions, through one or more trading plans intended to comply with Rule 10b5-1, through tender o…
Changes in Registrant’s Certifying Accountant. (a) Resignation of Previous Independent Registered Public Accounting Firm On October 15, 2025, the Audit Committee (the “Committee”) of the Board of Directors of Solana Corporation (formerly known as Helius Medical Technologies, Inc.) (the “Company”) received the resignation of Baker Tilly US, LLP (“Baker Tilly”) as the Company’s independent registered public accounting firm, effective immediately. The Committee accepted Baker Tilly’s resigna…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 24, 2025, Helius Medical Technologies, Inc. (the “Company”) entered into side letter agreements with Dane C. Andreeff, President and Chief Executive Officer, and Jeffrey S. Mathiesen, Chief Financial Officer, Treasurer and Secretary (together, the “Side Letters”). The Side Letters provide for one-time discretionary cash bonuses paid…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Director Appointment On September 18, 2025, the Board of Directors of the Company (the “Board”), pursuant to its powers under the Certificate of Incorporation, as amended, and the Second Amended and Restated Bylaws of the Company, approved an increase in the size of the Board from six (6) to seven (7) directors and the appointment of Joseph Chee as…
Entry into a Material Definitive Agreement As previously disclosed, on September 15, 2025, Helius Medical Technologies, Inc. (the “Company”) entered into subscription agreements (the “Cash Subscription Agreements”) with certain accredited investors (the “Cash Purchasers”) pursuant to which the Company, in a private placement (the “Cash Offering”), agreed to issue and sell to the Cash Purchasers an aggregate of (i) 37,825,277 shares of Class A common stock of the Company, par value $0.001 per…
to this Current Report, and in Exhibit 99.1 furnished herewith, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such a filing. Forward-Looking Statements This Current Report co…
Unregistered Sales of Equity Securities The disclosure required by this Item is included in
Entry into a Material Definitive Agreement. On September 15, 2025, Helius Medical Technologies, Inc. (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with Clear Street LLC (“Clear Street”) and Maxim Group LLC (“Maxim”) (each, an “Agent,” and, together, the “Agents”), as co-sales agents, pursuant to which the Company may offer and sell shares of the Company’s Class A common stock, par value $0.001 per share (the “Shares”) from time to time having an aggregate sales price…
Unregistered Sales of Equity Securities The disclosure required by this Item is included in
Regulation FD Disclosure. Press Release on Announcing the Offering On September 15, 2025, the Company issued a press release announcing the signing of the Purchase Agreements and pricing of the Offerings and estimated aggregate gross proceeds of approximately $500 million in cash, before deducting placement agent fees and other offering expenses, to implement a SOL treasury strategy. A copy of the press release is included as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated…
Entry into a Material Definitive Agreement. Securities Purchase Agreements On September 15, 2025, Helius Medical Technologies, Inc. (the “ Company ”) entered into securities purchase agreements (the “ Cash Securities Purchase Agreements ”) with certain accredited investors (the “ Cash Purchasers ”) pursuant to which the Company agreed to sell and issue to the Cash Purchasers in a private placement offering (the “ Cash Offering ”) an aggregate offering of (i) either shares (the “ Cash Shares ”…
Other Events. On July 21, 2025, Helius Medical Technologies, Inc. (the “Company”) announced the positive outcome of the Portable Neuromodulation Stimulator (“PoNS”) Stroke Registrational Program (“SRP”) and planned upcoming FDA submission seeking an indication for gait and balance deficit in patients with chronic symptoms of stroke under the current Breakthrough Device Designation. The key primary outcomes from the SRP indicate that (i) a double-blind randomized clinical trial met the prima…
Other Events. As previously disclosed, on June 23, 2023, Helius Medical Technologies, Inc., (the “Company”), entered into a Sales Agreement (the “Sales Agreement”) with Roth Capital Partners, LLC (the “Agent”), as sales agent, pursuant to which the Company may offer and sell shares of the Company’s common stock, par value $0.001 per share (the “Shares”). On July 7, 2025, the Company filed an updated Prospectus Supplement (the “Prospectus”) for the offer and sale of up to $25 million of Shares…
Material Modification to Rights of Security Holders. To the extent required by
Importance-ranked changes since the prior daily snapshot.
Management rose by 8.8 points (from 11.4 to 20.2).
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.